Citadel Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-21,316
| Closed | -$415K | – | 9655 |
|
|
2018
Q1 | $415K | Sell |
21,316
-33,581
| -61% | -$659K | ﹤0.01% | 6224 |
|
|
2017
Q4 | $914K | Sell |
54,897
-176,361
| -76% | -$3.23M | ﹤0.01% | 4775 |
|
|
2017
Q3 | $4.7M | Sell |
231,258
-1,953,355
| -89% | -$37.3M | ﹤0.01% | 2362 |
|
|
2017
Q2 | $35.2M | Buy |
2,184,613
+440,398
| +25% | +$6.51M | 0.03% | 669 |
|
|
2017
Q1 | $22.1M | Buy |
1,744,215
+1,534,509
| +732% | +$18.5M | 0.02% | 886 |
|
|
2016
Q4 | $2.78M | Sell |
209,706
-278,675
| -57% | -$4.76M | ﹤0.01% | 2579 |
|
|
2016
Q3 | $11.6M | Buy |
488,381
+225,949
| +86% | +$6.07M | 0.01% | 1246 |
|
|
2016
Q2 | $7.56M | Sell |
262,432
-305,353
| -54% | -$9.95M | 0.01% | 1465 |
|
|
2016
Q1 | $18.2M | Buy |
567,785
+183,333
| +48% | +$6.45M | 0.02% | 808 |
|
|
2015
Q4 | $16.4M | Buy |
384,452
+377,357
| +5,319% | +$15.1M | 0.02% | 949 |
|
|
2015
Q3 | $250K | Sell |
7,095
-257,643
| -97% | -$11.6M | ﹤0.01% | 5832 |
|
|
2015
Q2 | $12.2M | Buy |
264,738
+246,699
| +1,368% | +$11.7M | 0.01% | 1339 |
|
|
2015
Q1 | $845K | Buy |
18,039
+8,843
| +96% | +$352K | ﹤0.01% | 4155 |
|
|
2014
Q4 | $292K | Sell |
9,196
-93,816
| -91% | -$2.75M | ﹤0.01% | 5483 |
|
|
2014
Q3 | $2.44M | Buy |
+103,012
| New | +$2.64M | ﹤0.01% | 2636 |
|
|
2014
Q2 | – | Sell |
-151,726
| Closed | -$4.09M | – | 8528 |
|
|
2014
Q1 | $4.01M | Sell |
151,726
-756,874
| -83% | -$18.9M | ﹤0.01% | 1974 |
|
|
2013
Q4 | $22.8M | Sell |
908,600
-514,591
| -36% | -$11.5M | 0.03% | 730 |
|
|
2013
Q3 | $29.2M | Sell |
1,423,191
-98,944
| -7% | -$2.04M | 0.04% | 542 |
|
|
2013
Q2 | $30.4M | Buy |
+1,522,135
| New | +$27M | 0.05% | 446 |
|
Citadel Advisors's IPXL Position: Q2 2018 in Review
Citadel Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 21,316 shares — an estimated $415K sold.
Citadel Advisors first reported a position in IPXL in Q2 2013 and held it in 19 quarters. The position peaked at $35.2M in Q2 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Citadel Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Citadel Advisors sold 21,316 Impax Laboratories, Inc. shares in Q2 2018, an estimated $415K.
- Citadel Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 19 quarters.
- Citadel Advisors's Impax Laboratories, Inc. position peaked at $35.2M in Q2 2017.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.